Artificial Intelligence – Transforming Regulatory Affairs

In the domain of Pharmaceutical Regulatory Affairs, regulatory agencies such as EMA and FDA are harnessing the potential of Artifical Intelligence (AI) to revolutionise assessment and oversight. While EMA and FDA are in consultation with stakeholders, we explore AI’s transformative impact and potential challenges ahead. AI enables machines to learn, think, and perform human like tasks, particularly excelling in data analysis and decision making.